Compare CRNX & LRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | LRN |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2018 | 2007 |
| Metric | CRNX | LRN |
|---|---|---|
| Price | $40.24 | $99.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $76.63 | ★ $106.75 |
| AVG Volume (30 Days) | ★ 1.1M | 573.0K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.87 |
| EPS | N/A | ★ 3.49 |
| Revenue | $1,039,000.00 | ★ $917,734,000.00 |
| Revenue This Year | $720.10 | $6.18 |
| Revenue Next Year | $184.67 | $4.74 |
| P/E Ratio | ★ N/A | $28.21 |
| Revenue Growth | N/A | ★ 3.29 |
| 52 Week Low | $25.83 | $60.61 |
| 52 Week High | $57.99 | $171.17 |
| Indicator | CRNX | LRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 77.71 |
| Support Level | $39.35 | $81.27 |
| Resistance Level | $45.32 | $148.37 |
| Average True Range (ATR) | 1.44 | 2.64 |
| MACD | 0.56 | 0.88 |
| Stochastic Oscillator | 83.70 | 93.44 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.